HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

ICUI

ICU Medical, Inc. (NASDAQ)

Healthcare — Medical Instruments & Supplies

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

None 8 analysts
$157.44
$-1.33 (-0.84%)
Target: $172.50 (9.6%)
Sign in to add ICUI to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$3.71B
P/E Ratio (TTM)80.25
Forward P/E15.96
EPS (TTM)$1.85
Dividend Yield-
Profit Margin2.15%
Revenue Growth-12.30%
ROE2.26%
Debt/Equity63.62
Recommendation None
Analyst Target$172.50
Analysts8
Indexes NASDAQ

Technical Indicators

RSI (14)62.1
Beta0.78
SMA 20-
SMA 40-
52-Week High$160.29
52-Week Low$107.00
50-Day Avg$131.89
200-Day Avg$135.46
Avg Volume299.1K
Volume147.1K

Performance Analysis

NEUTRAL

ICUI presents a mixed picture with both positive and negative indicators.

- Trading near its 52-week high ($160.29), which may indicate limited upside.
+ RSI at 62.1 shows positive momentum.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- P/E of 80.2 is elevated — the market expects high growth or it may be overvalued.
- Revenue declined 12.3% year-over-year.
~ Wall Street consensus is "none" from 8 analysts.
+ Average analyst target of $172.50 implies 9.6% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:14 UTC

Back to Screener Export Report